Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

Suzhou Ribo Licenses siRNA Delivery System from Life Techologies

publication date: Jun 19, 2013
View a Printer Friendly version of this page, allowing you to print the page.
Suzhou Ribo Life Sciences and Life Technologies of California have stuck a deal giving Ribo exclusive China rights to develop and manufacture siRNA therapeutics using Life's Invivofectamine® Rx delivery technology. Life Technologies will receive milestones and royalties for each drug that Ribo develops. Ribo’s first product is a treatment for hepatitis B. Invivofectamine® was originally produced as a research tool for knocking out genes in small-animal research models. Invivofectamine® Rx is based around a new class of lipid molecules that is 100-fold more powerful than the research product, while being less toxic, according to Life. More details....

Stock Symbol: (NSDQ: LIFE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China